QSAM Biosciences to Provide Updates on its Clinical Trial at the Emerging Growth Conference on Wednesday, March 22, 2023
QSAM Biosciences (OTCQB: QSAM) is set to present updates on its clinical trial for CycloSam®, a next-generation therapeutic radiopharmaceutical targeting metastatic bone cancer, at the Emerging Growth Conference on March 22, 2023. The presentation will occur at 2:50 PM EST and will last approximately 10 minutes, allowing investors and analysts to engage with the company's executive team. CycloSam® has shown preliminary safety and efficacy in prior studies, and QSAM is optimistic about its commercialization path given its innovative technology. Interested parties can register online to attend.
- CycloSam® has demonstrated preliminary safety and efficacy in animal studies and a human trial.
- QSAM is optimistic about the commercialization pathway due to its innovative nuclear medicine technology.
- The presentation at the Emerging Growth Conference provides a platform for real-time investor engagement.
- None.
QSAM invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference.
Austin, TX, March 20, 2023 (GLOBE NEWSWIRE) -- QSAM Biosciences, Inc. (OTCQB: QSAM), a company developing next generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®), for the treatment of bone cancer and related diseases and conditions, is pleased to announce that it has been invited to provide updates on its clinical trial evaluating CycloSam® for the treatment of metastatic bone cancer at the Emerging Growth Conference on Wednesday, March 22, 2023, at 2:50 PM EST.
The Emerging Growth Conference is a live, interactive online event that will give existing shareholders and the investment community the opportunity to interact with the Company’s executive officers.
Douglas Baum, the Company’s CEO, and other executive officers of QSAM will provide a presentation and may subsequently open the floor for questions. Please submit your questions in advance to Questions@EmergingGrowth.com or ask your questions during the event if time allows.
QSAM will be presenting at 2:50 PM Eastern time for approximately 10 minutes. Please register here to ensure you are able to attend the conference and receive any updates that are released:
Link: Register Here to Attend QSAM’s Presentation
About the Emerging Growth Conference
The Emerging Growth conference is an effective way for public companies to present and communicate their new products, services and other major announcements to the investment community from the convenience of their office, in a time efficient manner.
The Conference focus and coverage includes companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and th overall potential for long term growth. Its audience includes potentially tens of thousands of Individual and Institutional investors, as well as Investment advisors and analysts. All sessions will be conducted through video webcasts and will take place in the Eastern time zone.
About QSAM Biosciences
QSAM Biosciences, Inc. is developing next-generation nuclear medicines for the treatment of cancer and related diseases. QSAM’s initial technology, CycloSam® (Samarium-153 DOTMP), is a clinical-stage bone-targeting radiopharmaceutical developed by IsoTherapeutics Group LLC, pioneers in the nuclear medicine space who also developed the FDA-approved Quadramet® (Samarium-153 EDTMP) radiopharmaceutical product, which is indicated for pain palliation. QSAM is led by an experienced executive team and board of directors that have completed numerous FDA approvals and multiple successful biotech exits.
CycloSam® has demonstrated preliminary safety and efficacy in animal studies and a single patient FDA-cleared human trial performed in 2020 at the Cleveland Clinic. This nuclear technology uses low specific activity Samarium-153 (resulting in far less long-lived europium impurities) and DOTMP, a chelator which is believed to reduce or eliminate off-target migration and targets sites of high bone turnover, making it, in management’s opinion, an ideal agent to treat primary and secondary bone cancers. Since CycloSam® delivers targeted radiation selectively to the skeletal system and to bone tumors, it is also believed to be a candidate for effectiveness trials in bone marrow ablation as preconditioning for bone marrow transplantation, as well as in procedures to reduce external beam radiation to bone tumors. This multi-patented drug candidate utilizes a radioisotope previously approved by the FDA combined with a novel chelant, DOTMP, that has demonstrated preliminary increased efficacy and decreased side effects in animal models and veterinary treatment of bone cancer in dogs. Further, CycloSam® utilizes a streamlined, just-in-time manufacturing process that is already in place. Given these factors, management believes there is a strong pathway to commercialization for CycloSam®.
Legal Notice Regarding Forward-Looking Statements: This news release contains "forward-looking statements.” These statements relate to future events or our future financial performance. These statements are only predictions and may differ materially from actual future results or events. We disclaim any intention or obligation to revise any forward-looking statements, whether as a result of new information, future developments or otherwise. There are important risk factors that could cause actual results to differ from those contained in forward-looking statements, including, but not limited to, our ability to fully commercialize our technology, risks associated with changes in general economic and business conditions, regulatory risks, clinical trial risks, early stage versus late-stage product safety and efficacy, actions of our competitors, the extent to which we are able to develop new products and markets, the time and expense involved in such development activities, the ability to secure additional financing, the ability to consummate acquisitions and ultimately integrate them, the level of demand and market acceptance of our products, climate-related risks and changes in our business strategies. This is not an offering of securities, and securities may not be offered or sold absent registration or an applicable exemption from the registration requirements.
Corporate Communications
Namrata Chand, VP Operations
ir@qsambio.com
FAQ
What is QSAM presenting at the Emerging Growth Conference?
When is QSAM's presentation scheduled?
What is CycloSam® and its significance?
How can investors interact during QSAM's presentation?
